Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration
NCT ID: NCT00259753
Last Updated: 2008-08-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
120 participants
INTERVENTIONAL
2005-07-31
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
0.2 mg/eye
Bevasiranib
2
1.5 mg/eye
Bevasiranib
3
3.0 mg/eye
Bevasiranib
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bevasiranib
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients must have ETDRS best corrected visual acuity of 64 to 24 letters (20/50 to 20/320 Snellen Equivalent) in the study eye.
3. Patients must be age 50 or older
Exclusion Criteria
2. Patients with advanced glaucoma (greater than 0.8 cup:disk) or intraocular pressure above 22 mmHg in the study eye.
3. Patients with any retinal vasculopathies, including diabetic retinopathy, retinal vein occlusions, etc. in the study eye.
4. Patients with any subfoveal scarring, atrophy, or hemorrhage in the study eye.
5. Patients whose CNV lesion in the study eye contains more than 25% scarring and/or atrophy.
6. Patients who have undergone any extrafoveal/juxtafoveal laser treatment of the study eye within two weeks prior to the screening visit.
7. Patients who received treatment with an investigational drug within 4 weeks prior to the screening visit.
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
OPKO Health, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Opko Health
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Denis O'Shaughnessy, PHD
Role: STUDY_DIRECTOR
Opko Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Acuity Participating Site
Phoenix, Arizona, United States
Retina Centers PC
Tucson, Arizona, United States
Sall Research Medical Center
Artesia, California, United States
Bay Area Retina Associates
Walnut Creek, California, United States
Florida Eye Microsurgical Institute, Inc.
Boynton Beach, Florida, United States
Retina Specialist
Towson, Maryland, United States
Vitreo-Retinal Associates PC
Grand Rapids, Michigan, United States
Associated Retinal Consultants
Grand Rapids, Michigan, United States
Associated Retinal Consultants, P.C.
Royal Oak, Michigan, United States
VitreoRetinal Surgery, P.A.
Edina, Minnesota, United States
Eye Foundation of Kansas City, UMKC School of Medicine
Kansas City, Missouri, United States
Retina-Vitreous Center
Lakewood, New Jersey, United States
Retina-Vitreous Consultants
Livingston, New Jersey, United States
OCLI
Lynbrook, New York, United States
LuEsther T. Mertz Retinal Research Center
New York, New York, United States
Southeast Clinical Research
Charlotte, North Carolina, United States
Retina Associates of Cleveland
Beachwood, Ohio, United States
Retina Associates of Cleveland, Inc.
Lakewood, Ohio, United States
Black Hills Eye Institute
Rapid City, South Dakota, United States
Retina Reseach Center
Austin, Texas, United States
Ophthalmology Associates
Fort Worth, Texas, United States
Vitreoretinal Consultants Houston TX
Houston, Texas, United States
Medical College of Wisconsin Eye Institute
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Sponsor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACU201
Identifier Type: -
Identifier Source: org_study_id